(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr21.80 | 8.25% | 19.84% |
| LNA SANTE (LNA.PA) | €20.45 | 2.4% | 7.98% |
| BIOMERIEUX (BIM.PA) | €102.25 | 0.87% | 8.73% |
| VIRBAC (VIRP.PA) | €346.00 | 0.39% | 13.84% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
8.25% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.17. Meaning, the purchaser of the share is investing kr17.17 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Volatility
VISTIN PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.12%, a negative 0.05%, and a positive 1.42%.
VISTIN PHARMA’s highest amplitude of average volatility was 1.53% (last week), 1.04% (last month), and 1.42% (last quarter).
Moving Average
VISTIN PHARMA’s worth is below its 50-day moving average of kr21.97 and under its 200-day moving average of kr22.75.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr21.80 at 12:30 EST, way under its 52-week high of kr24.90 and above its 52-week low of kr20.60.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
More news about VISTIN PHARMA.
2. LNA SANTE (LNA.PA)
2.4% Forward Dividend Yield and 7.98% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 736.08M for the twelve trailing months.
Moving Average
LNA SANTE’s value is way below its 50-day moving average of €25.76 and under its 200-day moving average of €21.75.
More news about LNA SANTE.
3. BIOMERIEUX (BIM.PA)
0.87% Forward Dividend Yield and 8.73% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.01.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 33.97. Meaning, the purchaser of the share is investing €33.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 7, 2024, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.87%.
More news about BIOMERIEUX.
4. VIRBAC (VIRP.PA)
0.39% Forward Dividend Yield and 13.84% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.1%, now sitting on 1.25B for the twelve trailing months.
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.49%, a negative 0.27%, and a positive 1.58%.
VIRBAC’s highest amplitude of average volatility was 1.49% (last week), 1.61% (last month), and 1.58% (last quarter).
Yearly Top and Bottom Value
VIRBAC’s stock is valued at €346.00 at 12:30 EST, under its 52-week high of €377.50 and way above its 52-week low of €239.00.
More news about VIRBAC.
